Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued on Tuesday. The brokerage set a “hold” rating on the stock.

Several other equities research analysts have also issued reports on EKSO. Lake Street Capital started coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They issued a “buy” rating and a $2.50 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Ekso Bionics in a research report on Tuesday, July 30th.

Ekso Bionics Price Performance

EKSO stock opened at $1.19 on Tuesday. The company has a market cap of $21.95 million, a PE ratio of -1.23 and a beta of 1.45. The company has a current ratio of 2.42, a quick ratio of 1.77 and a debt-to-equity ratio of 0.36. The stock has a 50-day moving average price of $1.12 and a two-hundred day moving average price of $1.21. Ekso Bionics has a 12-month low of $0.62 and a 12-month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $4.95 million for the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same quarter in the previous year, the firm posted ($0.31) EPS. As a group, research analysts predict that Ekso Bionics will post -0.42 EPS for the current year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC lifted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.